HealthDay - FRIDAY, Oct. 7 (HealthDay News) -- News that a key government advisory panel will give a thumbs-down next week to a controversial blood test for prostate cancer is garnering both praise and condemnation from experts.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.